| MDL | MFCD22580413 |
|---|---|
| Molecular Weight | 506.02 |
| Molecular Formula | C25H24ClN7OS |
| SMILES | O=C(C1=NC2=CC=CC=C2N=C1)NC3=C(C=CC=C3)C4=CN5C(CN6CCNCC6)=CSC5=N4.Cl |
|
SIRT1 0.10 μM (EC 50 ) |
SIRT1 0.16 μM (EC1.5) |
SIRT2 37 μM (EC1.5) |
SRT 1720 effectively decreases the acetylation of p53 in cells even in the absence of SIRT1, and this is attributed to inhibition of histone acetyltransferase p300 [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
SRT 1720 (10, 30, 100 mg/kg, p.o.) treatment significantly reduces fasting blood glucose to near normal levels in
Lep
ob/ob
mice
[1]
.
SRT 1720 has ability to protect against the negative effects of diet-induced obesity in mice, and has a connection to metabolic adaptation in fatty acid and oxidative metabolism through downstream targets of SIRT1 such as PGC1α and FOXO1
[2]
.
SRT 1720 (50-100 mg/kg, p.o.), during emphysema development attenuates elastase-induced airspace enlargement and lung function impairment as well as reduces arterial oxygen saturation in WT mice
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Solid
Room temperature in continental US; may vary elsewhere.
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
DMSO : 62.5 mg/mL ( 123.51 mM ; Need ultrasonic)
H 2 O : 15.7 mg/mL ( 31.03 mM ; Need ultrasonic and warming)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.9762 mL | 9.8810 mL | 19.7621 mL |
| 5 mM | 0.3952 mL | 1.9762 mL | 3.9524 mL |
| 10 mM | 0.1976 mL | 0.9881 mL | 1.9762 mL |
Add each solvent one by one: 0.5% HPMC >> 0.2%Tween80
Solubility: 10 mg/mL (19.76 mM); Suspened solution; Need ultrasonic
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (4.11 mM); Clear solution
Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)
Solubility: ≥ 1 mg/mL (1.98 mM); Clear solution